Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Tuberculosis

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 82 articles: HTML format

Single Articles

September 2025
1. PEROUTKA-BIGUS N, Scherman MS, Kaya F, Waidyarachchi SL, et al
   Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis.
   Antimicrob Agents Chemother. 2025 Sep 30:e0118325. doi: 10.1128/aac.01183.
   PubMed     Abstract available
   
   
   
2. SINGH S, Devine M, Gumbo T, Srivastava S, et al
   Epetraborole pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2025 Sep 22:e0048125. doi: 10.1128/aac.00481.
   PubMed     Abstract available
   
   
   
3. RUPASINGHE P, Ismail N, Mulders W, Warren RM, et al
   In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2025 Sep 22:e0111325. doi: 10.1128/aac.01113.
   PubMed     Abstract available
   
   
   
4. BALDIN VP, Harding CL, Quach D, Sugie J, et al
   Thienopyrimidine amide analogs target MmpL3 in Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2025 Sep 22:e0098025. doi: 10.1128/aac.00980.
   PubMed     Abstract available
   
   
   
5. WYNN EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, et al
   Deconvoluting drug interactions using M. tuberculosis physiologic processes: transcriptional disaggregation of the BPaL regimen in vivo.
   Antimicrob Agents Chemother. 2025 Sep 18:e0049225. doi: 10.1128/aac.00492.
   PubMed     Abstract available
   
   
   
6. KIRUBAKAR G, Johnston L, Nae Rin Lee B, Russell DG, et al
   Incorporation of macrophage immune stresses into an intracellular assay of drug tolerance in Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2025 Sep 11:e0079525. doi: 10.1128/aac.00795.
   PubMed     Abstract available
   
   
   
7. RESENDIZ-GALVAN JE, Arora PR, Lokhande RV, Udwadia ZF, et al
   Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis.
   Antimicrob Agents Chemother. 2025 Sep 2:e0010125. doi: 10.1128/aac.00101.
   PubMed     Abstract available
   
   
   August 2025
8. ZHANG M, Allen R, Ames L, Engelhart CA, et al
   Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2025 Aug 19:e0036825. doi: 10.1128/aac.00368.
   PubMed     Abstract available
   
   
   
9. ISMAIL N, Sirgel F, Omar SV, Omar S, et al
   Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing.
   Antimicrob Agents Chemother. 2025;69:e0035625.
   PubMed     Abstract available
   
   
   July 2025
10. VAN SCHALKWYK M, Bekker A, Decloedt E, Wang J, et al
    Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study.
    Antimicrob Agents Chemother. 2025 Jul 31:e0005225. doi: 10.1128/aac.00052.
    PubMed     Abstract available
    
    
    
11. LIANG L, Quigley J, Theriault M, Iinishi A, et al
    A chlorinated diketopiperazine antibiotic targets Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Jul 31:e0036925. doi: 10.1128/aac.00369.
    PubMed     Abstract available
    
    
    
12. CALDERIN JM, Wasserman S, Resendiz-Galvan JE, Abdelgawad N, et al
    Population pharmacokinetics of pyrazinamide and isoniazid in plasma and cerebrospinal fluid from South African adults with tuberculous meningitis.
    Antimicrob Agents Chemother. 2025 Jul 1:e0009925. doi: 10.1128/aac.00099.
    PubMed     Abstract available
    
    
    June 2025
13. PEROUTKA-BIGUS N, Brooks EJ, Ramey ME, D'Erasmo H, et al
    Erratum for Peroutka-Bigus et al., "Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease".
    Antimicrob Agents Chemother. 2025 Jun 26:e0065425. doi: 10.1128/aac.00654.
    PubMed    
    
    
    May 2025
14. ARMESILLA-DIAZ A, Pilar Arenaz M, Ashby C, Blanco D, et al
    High-throughput screening of small molecules targeting Mycobacterium tuberculosis in human iPSC macrophages.
    Antimicrob Agents Chemother. 2025 May 27:e0161324. doi: 10.1128/aac.01613.
    PubMed     Abstract available
    
    
    April 2025
15. SONI H, Tyagi S, Mane K, Shelke AM, et al
    The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 23:e0013025. doi: 10.1128/aac.00130.
    PubMed     Abstract available
    
    
    
16. LI D, Li L, Zhang Y, Cheng K, et al
    Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 22:e0001925. doi: 10.1128/aac.00019.
    PubMed     Abstract available
    
    
    
17. SZEL V, Phelan JE, Georghiou SB, Dolinger DL, et al
    The ahpC c-54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 22:e0026525. doi: 10.1128/aac.00265.
    PubMed     Abstract available
    
    
    
18. ARDIZZONI E, Mulders W, De Diego Fuertes M, Hayrapetyan A, et al
    Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from Armenia.
    Antimicrob Agents Chemother. 2025 Apr 9:e0183924. doi: 10.1128/aac.01839.
    PubMed     Abstract available
    
    
    
19. SAWE S, Tsirizani L, Court R, Gausi K, et al
    The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 1:e0162624. doi: 10.1128/aac.01626.
    PubMed     Abstract available
    
    
    March 2025
20. PEROUTKA-BIGUS N, Brooks EJ, Ramey ME, D'Erasmo H, et al
    Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease.
    Antimicrob Agents Chemother. 2025 Mar 26:e0190124. doi: 10.1128/aac.01901.
    PubMed     Abstract available
    
    
    
21. VEVE MP, Kenney RM, Aljundi AM, Dierker MS, et al
    Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacterium infections in the United States.
    Antimicrob Agents Chemother. 2025 Mar 4:e0159624. doi: 10.1128/aac.01596.
    PubMed     Abstract available
    
    
    February 2025
22. GHEBREKRISTOS Y, Ahmed A, Beylis N, Singh S, et al
    Xpert MTB/RIF Ultra-resistant and MTBDRplus-susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing.
    Antimicrob Agents Chemother. 2025 Feb 7:e0167124. doi: 10.1128/aac.01671.
    PubMed     Abstract available
    
    
    January 2025
23. WYNN EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, et al
    Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice.
    Antimicrob Agents Chemother. 2025 Jan 17:e0131024. doi: 10.1128/aac.01310.
    PubMed     Abstract available
    
    
    
24. VOGENSEN VB, Singh S, Allende CJ, Engelthaler DM, et al
    Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis.
    Antimicrob Agents Chemother. 2025 Jan 16:e0108424. doi: 10.1128/aac.01084.
    PubMed     Abstract available
    
    
    December 2024
25. NDZAMBA B, Denti P, McIlleron H, Smith P, et al
    Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV.
    Antimicrob Agents Chemother. 2024 Dec 23:e0120024. doi: 10.1128/aac.01200.
    PubMed     Abstract available
    
    
    
26. MANSJO M, Espinosa-Gongora C, Samanci I, Groenheit R, et al
    Performance of a broth microdilution assay for routine minimum inhibitory concentration determination of 14 anti-tuberculous drugs against the Mycobacterium tuberculosis complex based on the EUCAST reference protocol.
    Antimicrob Agents Chemother. 2024 Dec 18:e0094624. doi: 10.1128/aac.00946.
    PubMed     Abstract available
    
    
    
27. KOMM OD, Tyagi S, Garcia A, Almeida D, et al
    Contribution of telacebec to novel drug regimens in a murine tuberculosis model.
    Antimicrob Agents Chemother. 2024 Dec 9:e0096224. doi: 10.1128/aac.00962.
    PubMed     Abstract available
    
    
    November 2024
28. VOCAT A, Luraschi-Eggemann A, Antoni C, Cathomen G, et al
    Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis.
    Antimicrob Agents Chemother. 2024 Nov 27:e0131824. doi: 10.1128/aac.01318.
    PubMed     Abstract available
    
    
    October 2024
29. SNOBRE J, Meehan CJ, Mulders W, Rigouts L, et al
    Frameshift mutations in the mmpR5 gene can have a bedaquiline-susceptible phenotype by retaining a protein structure and function similar to wild-type Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Oct 24:e0085424. doi: 10.1128/aac.00854.
    PubMed     Abstract available
    
    
    
30. MAITRE T, Godmer A, Mory C, Chauffour A, et al
    Levofloxacin activity at increasing doses in a murine model of fluoroquinolone-susceptible and -resistant tuberculosis.
    Antimicrob Agents Chemother. 2024 Oct 16:e0058324. doi: 10.1128/aac.00583.
    PubMed     Abstract available
    
    
    
31. GOH JJN, Wang Q, Zhang N, de Castro Suarez N, et al
    Prospectively predicting BPaMZ phase IIb/III trial outcomes using a translational mouse-to-human platform.
    Antimicrob Agents Chemother. 2024;68:e0061524.
    PubMed     Abstract available
    
    
    September 2024
32. ENCINAS L, Li S-Y, Rullas-Trincado J, Tasneen R, et al
    Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2024 Sep 30:e0035724. doi: 10.1128/aac.00357.
    PubMed     Abstract available
    
    
    
33. BAUMAN AA, Sarathy JP, Kaya F, Massoudi LM, et al
    Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis.
    Antimicrob Agents Chemother. 2024 Sep 30:e0071624. doi: 10.1128/aac.00716.
    PubMed     Abstract available
    
    
    
34. ALLEN R, Ames L, Baldin VP, Butts A, et al
    An arylsulfonamide that targets cell wall biosynthesis in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Sep 26:e0103724. doi: 10.1128/aac.01037.
    PubMed     Abstract available
    
    
    
35. POONAWALA H, Zhang Y, Kuchibhotla S, Green AG, et al
    Erratum for Poonawala et al., "Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis".
    Antimicrob Agents Chemother. 2024 Sep 19:e0135424. doi: 10.1128/aac.01354.
    PubMed    
    
    
    August 2024
36. MARTINI MC, Alonso MN, Cafiero JH, Xiao J, et al
    Loss of glycerol catabolism confers carbon-source-dependent artemisinin resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Aug 28:e0064524. doi: 10.1128/aac.00645.
    PubMed     Abstract available
    
    
    July 2024
37. ROBERTS AH, Moon CW, Faulkner V, Kendall SL, et al
    EfpA is required for regrowth of Mycobacterium tuberculosis following isoniazid exposure.
    Antimicrob Agents Chemother. 2024 Jul 22:e0026124. doi: 10.1128/aac.00261.
    PubMed     Abstract available
    
    
    
38. SEMERE GEBREYESUS M, Wasmann RE, McIlleron H, Oladokun R, et al
    Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy.
    Antimicrob Agents Chemother. 2024 Jul 22:e0035424. doi: 10.1128/aac.00354.
    PubMed     Abstract available
    
    
    
39. WASSERMAN S, Antilus-Sainte R, Abdelgawad N, Odjourian NM, et al
    Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis.
    Antimicrob Agents Chemother. 2024 Jul 19:e0078324. doi: 10.1128/aac.00783.
    PubMed     Abstract available
    
    
    
40. SIMEON S, Garcia-Cremades M, Savic R, Solans BP, et al
    Pharmacokinetic-pharmacodynamic modeling of tuberculosis time to positivity and colony-forming unit to assess the response to dose-ranging linezolid.
    Antimicrob Agents Chemother. 2024 Jul 17:e0019024. doi: 10.1128/aac.00190.
    PubMed     Abstract available
    
    
    June 2024
41. KURTZHALS ML, Norman A, Svensson E, Lillebaek T, et al
    Applying whole genome sequencing to predict phenotypic drug resistance in Mycobacterium tuberculosis: leveraging 20 years of nationwide data from Denmark.
    Antimicrob Agents Chemother. 2024 Jun 21:e0043024. doi: 10.1128/aac.00430.
    PubMed     Abstract available
    
    
    
42. MOTTA I, Cusinato M, Ludman AJ, Lachenal N, et al
    How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Antimicrob Agents Chemother. 2024 Jun 6:e0053624. doi: 10.1128/aac.00536.
    PubMed     Abstract available
    
    
    
43. NEGATU DA, Aragaw WW, Dartois V, Dick T, et al
    A pairwise approach to revitalize beta-lactams for the treatment of TB.
    Antimicrob Agents Chemother. 2024;68:e0003424.
    PubMed     Abstract available
    
    
    
44. WALSH KF, Lee MH, Zainabadi K, Vilbrun SC, et al
    High variance in quantification of Mycobacterium tuberculosis at low bacterial loads and with differentially detectable mycobacteria.
    Antimicrob Agents Chemother. 2024 Jun 3:e0160123. doi: 10.1128/aac.01601.
    PubMed     Abstract available
    
    
    May 2024
45. YU W, Ju Y, Han X, Tian X, et al
    Bactericidal and sterilizing activity of sudapyridine-clofazimine-TB47 combined with linezolid or pyrazinamide in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2024 May 1:e0012424. doi: 10.1128/aac.00124.
    PubMed     Abstract available
    
    
    April 2024
46. KENGO A, Nabeemeeah F, Denti P, Sabet R, et al
    Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2024 Apr 10:e0158323. doi: 10.1128/aac.01583.
    PubMed     Abstract available
    
    
    
47. POONAWALA H, Zhang Y, Kuchibhotla S, Green AG, et al
    Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Apr 8:e0118523. doi: 10.1128/aac.01185.
    PubMed     Abstract available
    
    
    March 2024
48. LYONS MA, Obregon-Henao A, Ramey ME, Bauman AA, et al
    Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis.
    Antimicrob Agents Chemother. 2024 Mar 19:e0101023. doi: 10.1128/aac.01010.
    PubMed     Abstract available
    
    
    
49. VILLELLAS C, Stevenaert F, Remmerie B, Andries K, et al
    Sub-MIC levels of bedaquiline and clofazimine can select Mycobacterium tuberculosis mutants with increased MIC.
    Antimicrob Agents Chemother. 2024 Mar 12:e0127523. doi: 10.1128/aac.01275.
    PubMed     Abstract available
    
    
    February 2024
50. OLIVENCA F, Pires D, Silveiro C, Gama B, et al
    Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Feb 27:e0158623. doi: 10.1128/aac.01586.
    PubMed     Abstract available
    
    
    
51. LI S-Y, Tyagi S, Soni H, Betoudji F, et al
    Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2024 Feb 20:e0156223. doi: 10.1128/aac.01562.
    PubMed     Abstract available
    
    
    January 2024
52. SINGH P, Kumar A, Sharma P, Chugh S, et al
    Identification and optimization of pyridine carboxamide-based scaffold as a drug lead for Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Jan 9:e0076623. doi: 10.1128/aac.00766.
    PubMed     Abstract available
    
    
    December 2023
53. RUELAS CASTILLO J, Neupane P, Karanika S, Krug S, et al
    The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model.
    Antimicrob Agents Chemother. 2023 Dec 22:e0104323. doi: 10.1128/aac.01043.
    PubMed     Abstract available
    
    
    
54. SINGH S, Gumbo T, Boorgula GD, Thomas TA, et al
    Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model.
    Antimicrob Agents Chemother. 2023 Dec 22:e0108023. doi: 10.1128/aac.01080.
    PubMed     Abstract available
    
    
    
55. ALI AM, P Solans B, Hesseling AC, Winckler J, et al
    Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis.
    Antimicrob Agents Chemother. 2023 Dec 19:e0079423. doi: 10.1128/aac.00794.
    PubMed     Abstract available
    
    
    
56. PANDEY S, Vilcheze C, Werngren J, Bainomugisa A, et al
    Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2023 Dec 1:e0109623. doi: 10.1128/aac.01096.
    PubMed     Abstract available
    
    
    November 2023
57. VAN DER LAAN LE, Garcia-Prats AJ, McIlleron H, Abdelwahab MT, et al
    Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis.
    Antimicrob Agents Chemother. 2023 Nov 16:e0061123. doi: 10.1128/aac.00611.
    PubMed     Abstract available
    
    
    
58. ALMEIDA D, Li S-Y, Lee J, Hafkin B, et al
    Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2023 Nov 15:e0078923. doi: 10.1128/aac.00789.
    PubMed     Abstract available
    
    
    
59. LANNI F, Antilus Sainte R, Hansen M Jr, Parigi P, et al
    A preclinical model of TB meningitis to determine drug penetration and activity at the sites of disease.
    Antimicrob Agents Chemother. 2023 Nov 15:e0067123. doi: 10.1128/aac.00671.
    PubMed     Abstract available
    
    
    October 2023
60. VAN SCHALKWYK M, Bekker A, Decloedt E, Wang J, et al
    Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s.
    Antimicrob Agents Chemother. 2023 Oct 26:e0073723. doi: 10.1128/aac.00737.
    PubMed     Abstract available
    
    
    
61. XIE YL, Modi N, Handler D, Yu S, et al
    Simplified urine-based method to detect rifampin underexposure in adults with tuberculosis: a prospective diagnostic accuracy study.
    Antimicrob Agents Chemother. 2023 Oct 25:e0093223. doi: 10.1128/aac.00932.
    PubMed     Abstract available
    
    
    
62. KENGO A, Nabisere R, Gausi K, Musaazi J, et al
    Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin.
    Antimicrob Agents Chemother. 2023 Oct 18:e0043023. doi: 10.1128/aac.00430.
    PubMed     Abstract available
    
    
    
63. KENGO A, Gausi K, Nabisere R, Musaazi J, et al
    Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.
    Antimicrob Agents Chemother. 2023 Oct 18:e0043123. doi: 10.1128/aac.00431.
    PubMed     Abstract available
    
    
    
64. RAMEY ME, Kaya F, Bauman AA, Massoudi LM, et al
    Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model.
    Antimicrob Agents Chemother. 2023 Oct 4:e0059723. doi: 10.1128/aac.00597.
    PubMed     Abstract available
    
    
    September 2023
65. STEMKENS R, Jager V, Dawson R, Diacon AH, et al
    Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2023 Sep 28:e0068323. doi: 10.1128/aac.00683.
    PubMed     Abstract available
    
    
    
66. MEIKLE V, Zhang L, Niederweis M
    Intricate link between siderophore secretion and drug efflux in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2023 Sep 7:e0162922. doi: 10.1128/aac.01629.
    PubMed     Abstract available
    
    
    August 2023
67. WALTER ND, Ernest JP, Dide-Agossou C, Bauman AA, et al
    Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses.
    Antimicrob Agents Chemother. 2023 Aug 11:e0028423. doi: 10.1128/aac.00284.
    PubMed     Abstract available
    
    
    June 2023
68. ALI AM, Radtke KK, Hesseling AC, Winckler J, et al
    QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
    Antimicrob Agents Chemother. 2023 Jun 26:e0144822. doi: 10.1128/aac.01448.
    PubMed     Abstract available
    
    
    
69. GRIES R, Dal Molin M, Chhen J, van Gumpel E, et al
    Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome bc(1) Complex.
    Antimicrob Agents Chemother. 2023 Jun 26:e0025123. doi: 10.1128/aac.00251.
    PubMed     Abstract available
    
    
    
70. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, et al
    Erratum for van der Laan et al., "Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis".
    Antimicrob Agents Chemother. 2023 Jun 20:e0072023. doi: 10.1128/aac.00720.
    PubMed    
    
    
    
71. CHANG YS, Li SY, Pertinez H, Betoudji F, et al
    Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy.
    Antimicrob Agents Chemother. 2023 Jun 14:e0048123. doi: 10.1128/aac.00481.
    PubMed     Abstract available
    
    
    May 2023
72. XU J, Li D, Shi J, Wang B, et al
    Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis.
    Antimicrob Agents Chemother. 2023 May 31:e0153222. doi: 10.1128/aac.01532.
    PubMed     Abstract available
    
    
    
73. DAWSON R, Diacon AH, Narunsky K, De Jager VR, et al
    Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832.
    Antimicrob Agents Chemother. 2023 May 23:e0147722. doi: 10.1128/aac.01477.
    PubMed     Abstract available
    
    
    
74. MATHIYAZAKAN V, Wong CF, Harikishore A, Pethe K, et al
    Cryo-Electron Microscopy Structure of the Mycobacterium tuberculosis Cytochrome bcc:aa(3) Supercomplex and a Novel Inhibitor Targeting Subunit Cytochrome cI.
    Antimicrob Agents Chemother. 2023 May 9:e0153122. doi: 10.1128/aac.01531.
    PubMed     Abstract available
    
    
    April 2023
75. ZHU Y, Zhu L, Davies Forsman L, Paues J, et al
    Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
    Antimicrob Agents Chemother. 2023 Apr 25:e0170022. doi: 10.1128/aac.01700.
    PubMed     Abstract available
    
    
    
76. NEGATU DA, Aragaw WW, Cangialosi J, Dartois V, et al
    Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections.
    Antimicrob Agents Chemother. 2023;67:e0165522.
    PubMed     Abstract available
    
    
    
77. LIU Y, Moodley M, Pasipanodya JG, Gumbo T, et al
    Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.
    Antimicrob Agents Chemother. 2023;67:e0140122.
    PubMed     Abstract available
    
    
    March 2023
78. ECKHARDT E, Li Y, Mamerow S, Schinkothe J, et al
    Pharmacokinetics and Efficacy of the Benzothiazinone BTZ-043 against Tuberculous Mycobacteria inside Granulomas in the Guinea Pig Model.
    Antimicrob Agents Chemother. 2023 Mar 28:e0143822. doi: 10.1128/aac.01438.
    PubMed     Abstract available
    
    
    
79. LI SY, Converse PJ, Betoudji F, Lee J, et al
    Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
    Antimicrob Agents Chemother. 2023 Mar 15:e0003523. doi: 10.1128/aac.00035.
    PubMed     Abstract available
    
    
    
80. ISMAIL N, Dippenaar A, Warren RM, Peters RPH, et al
    Emergence of Canonical and Noncanonical Genomic Variants following In Vitro Exposure of Clinical Mycobacterium tuberculosis Strains to Bedaquiline or Clofazimine.
    Antimicrob Agents Chemother. 2023 Mar 9:e0136822. doi: 10.1128/aac.01368.
    PubMed     Abstract available
    
    
    February 2023
81. ABDELGAWAD N, Tshavhungwe MP, Rohlwink U, McIlleron H, et al
    Population Pharmacokinetic Analysis of Rifampicin in Plasma, Cerebrospinal Fluid, and Brain Extracellular Fluid in South African Children with Tuberculous Meningitis.
    Antimicrob Agents Chemother. 2023 Feb 23:e0147422. doi: 10.1128/aac.01474.
    PubMed     Abstract available
    
    
    
82. CHIREHWA MT, Resendiz-Galvan JE, Court R, De Kock M, et al
    Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
    Antimicrob Agents Chemother. 2023 Feb 6:e0142622. doi: 10.1128/aac.01426.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.